- Home
- PKBK vs ADCT Comparison
PKBK vs ADCT Comparison
Compare PKBK & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKBK
- ADCT
- Stock Information
- Founded
- PKBK 1999
- ADCT 2011
- Country
- PKBK United States
- ADCT Switzerland
- Employees
- PKBK 108
- ADCT N/A
- Industry
- PKBK Major Banks
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- PKBK Finance
- ADCT Health Care
- Exchange
- PKBK Nasdaq
- ADCT Nasdaq
- Market Cap
- PKBK 241.2M
- ADCT 241.0M
- IPO Year
- PKBK N/A
- ADCT 2020
- Fundamental
- Price
- PKBK $21.48
- ADCT $2.88
- Analyst Decision
- PKBK
- ADCT Strong Buy
- Analyst Count
- PKBK 0
- ADCT 6
- Target Price
- PKBK N/A
- ADCT $7.80
- AVG Volume (30 Days)
- PKBK 25.1K
- ADCT 915.5K
- Earning Date
- PKBK 07-18-2025
- ADCT 08-05-2025
- Dividend Yield
- PKBK 3.35%
- ADCT N/A
- EPS Growth
- PKBK 24.08
- ADCT N/A
- EPS
- PKBK 2.41
- ADCT N/A
- Revenue
- PKBK $64,206,999.00
- ADCT $75,817,000.00
- Revenue This Year
- PKBK N/A
- ADCT $10.65
- Revenue Next Year
- PKBK N/A
- ADCT $15.05
- P/E Ratio
- PKBK $8.93
- ADCT N/A
- Revenue Growth
- PKBK N/A
- ADCT 10.49
- 52 Week Low
- PKBK $15.44
- ADCT $1.05
- 52 Week High
- PKBK $24.29
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- PKBK 71.48
- ADCT 51.19
- Support Level
- PKBK $20.37
- ADCT $2.55
- Resistance Level
- PKBK $20.92
- ADCT $2.88
- Average True Range (ATR)
- PKBK 0.49
- ADCT 0.25
- MACD
- PKBK 0.20
- ADCT -0.09
- Stochastic Oscillator
- PKBK 96.09
- ADCT 21.13
About PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).